Author Archives: Halo Labs

AAVs: The future of gene therapies, but what will it take to make them stable?

Characterize adeno-associated viruses (AAVs) for aggregation, stability, and particles at low volume for accelerated development of life-saving gene therapies. Development can further be accelerated by monitoring critical quality attribute parameters like subvisible particles (SVP) concentration early in the development process. Capsid degradation and nucleic acid leakage can both occur under different formulation and storage conditions and contribute to the accumulation of aggregates. Characterizing candidates earlier in the development process is best as it identifies and eliminates inherently unstable candidates before…